ArticleCell reports2022
Mobilizing phospholipids on tumor plasma membrane implicates phosphatidylserine externalization blockade for cancer immunotherapy.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 44 citations in OpenAlex.
- Ultrasound-Activated Nanoinhibitors Blocking the Chemo-Immune Checkpoint to Overcome Chemotherapy-Induced Immune Resistance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- CD300ld on pathologically activated neutrophils promotes tumor immune suppression by binding phosphatidylserine on CD8Nature cancer · 2026Article
- Article
- Targeting TYRO3 attenuates apoptotic cell-driven cancer stemness in triple negative breast cancer.Cell communication and signaling : CCS · 2026Article
- Recent advances in preclinical studies combining hyperthermia therapy with novel immune checkpoint targeting agents.Frontiers in immunology · 2026Review
- A bacterial toxin as a novel anti-cancer drug modulating the tumor-microenvironment.Cell death & disease · 2025Article
- Phospholipid scramblases TMEM16F and Xkr8 mediate distinct features of phosphatidylserine (PS) externalization and immune suppression to promote tumor growth.Cell death discovery · 2025Article
- TMEM16F phospholipid scramblase regulates tumorigenesis by modulating the tumor immune microenvironment.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Review
- MALMPS: A Machine Learning-Based Metabolic Gene Prognostic Signature for Stratifying Clinical Outcomes and Molecular Heterogeneity in Stage II/III Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Nucleic acid-based delivery system delivering platinum drugs cooperates with siRNA for potentiated chemo-immunotherapy by reducing phosphatidylserine exposure and activating the cGAS-STING pathway.Acta pharmaceutica Sinica. B · 2025Article
- Apoptotic cells promote circulating tumor cell survival and metastasis.Communications biology · 2025Article
- Dys-regulated phosphatidylserine externalization as a cell intrinsic immune escape mechanism in cancer.Cell communication and signaling : CCS · 2025Review
- Phosphatidylserine (PS)-targeting chimeric Interferon (IFN) fusion proteins for anti-tumor applications.bioRxiv : the preprint server for biology · 2025Article
- Cationic antimicrobial peptides: potential templates for anticancer agents.Frontiers in medicine · 2025Review
- A pan-family screen of nuclear receptors in immunocytes reveals ligand-dependent inflammasome control.Immunity · 2024Article
- Targeted intracellular delivery of molecular cargo to hypoxic human breast cancer stem cells.bioRxiv : the preprint server for biology · 2024Article
- "Find Me" and "Eat Me" signals: tools to drive phagocytic processes for modulating antitumor immunity.Cancer communications (London, England) · 2024Review
- Knocking down of Xkr8 enhances chemotherapy efficacy through modulating tumor immune microenvironment.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Functional genomics identifies N-acetyllactosamine extension of complex N-glycans as a mechanism to evade lysis by natural killer cells.Cell reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Weihong WangTumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Shaoxian WuDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Zhanpeng CenTumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA; School of Medicine, Tsinghua University, Beijing, China.
Yixin ZhangTumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Yuang ChenCenter for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA 15261, USA.
Yixian HuangCenter for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA 15261, USA.
Anthony R CilloTumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Joshua S ProkopecTumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Giovanni QuaratoDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Dario A A VignaliTumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, 5115 Center Avenue, Pittsburgh, PA 15213, USA.
Jacob Stewart-OrnsteinDepartment of Computational and Systems Biology, Hillman Cancer Center and University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Song LiCenter for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA 15261, USA.
Binfeng LuDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, 5115 Center Avenue, Pittsburgh, PA 15213, USA. Electronic address: binfeng@pitt.edu.
Yi-Nan GongTumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, 5115 Center Avenue, Pittsburgh, PA 15213, USA. Electronic address: yngong@pitt.edu.
University of Pittsburgh · USUPMC Hillman Cancer Center · USSt. Jude Children's Research Hospital · USTsinghua University · CN
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0MWILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 2004 to 2026
$49.6MProject 5: Microenvironment manipulation using anti-angiogenics to improve immunotherapy in melanomaP50CA254865 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN, ZAROUR, HASSANE M · 2021 to 2025
$10.4MRegulatory T cells and the tumor microenvironmentR35CA263850 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Dario AA Vignali · 2021 to 2026
$5.4MNecrotic survivors and plasma membrane integrity signalingDP2GM146320 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GONG, YI-NAN · 2021 to 2024
$2.3MImmunostimulatory Nanocarrier for Breast Cancer ImmunochemotherapyR01CA219399 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LI, SONG · 2017 to 2021
$2.3MStudy of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapyR01CA254274 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LU, BINFENG · 2021 to 2025
$1.9MStudy of Interleukin 33 as a new immunotherapy of lung cancerR01CA239716 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LI, SONG, LU, BINFENG · 2019 to 2023
$1.8MNanotherapeutics for Synergistic Targeting of Myc in Prostate CancerR01CA223788 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LI, SONG · 2018 to 2022
$1.8MTargeted Combination Therapy for Breast CancerR01CA174305 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LI, SONG · 2014 to 2018
$1.6MDefining and manipulating quiescence associated DNA damage resistance in single cellsR00CA207727 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI STEWART-ORNSTEIN, JACOB · 2019 to 2021
$735kNCI NIH HHS P30 CA047904NCI NIH HHS P50 CA097190NCI NIH HHS P50 CA254865NCI NIH HHS R00 CA207727NCI NIH HHS R01 CA174305NCI NIH HHS R01 CA219399NCI NIH HHS R01 CA223788NCI NIH HHS R01 CA239716NCI NIH HHS R01 CA254274NCI NIH HHS R35 CA263850NIGMS NIH HHS DP2 GM146320
Abstract
In "healthy" tumor cells, phosphatidylserine (PS) is predominately localized in the inner plasma membrane leaflet. During apoptosis, PS relocates to the outer leaflet. Herein, we established PS
Indexed as
NeoplasmsPhosphatidylserinesApoptosisCell MembraneHumansImmunotherapyPhospholipidsPhosphatidylserinesPhospholipidscancer immunotherapyCDC50aCP: Cancerphosphatidylserine externalizationSTINGXkr8
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.